The report also includes the analysis of North American CINV market. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global CINV market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The competition in global CINV market is fragmented as the specific treatment for CINV is still at a nascent stage with several drugs by multiple competitors already thriving the market and some are under formulation.
The key players of the global CINV market, Heron Therapeutics, Inc., Merck & Co., Inc., Novartis AG and TESARO, Inc. are also profiled with their financial information and respective business strategies
- North America
- Heron Therapeutics, Inc.
- Merck & Co., Inc.
- Novartis AG
- TESARO, Inc.
Chemotherapy induced nausea and vomiting (CINV) is the most dreaded side-effect of chemotherapy among the cancer patients. Therefore, sometimes patients either do not undergo the chemotherapy or discontinue in the prior year of treatment. CINV is also of various types such as acute, breakthrough, delayed, anticipatory and refractory. HEC and MEC regimens cause the CINV. Several treatments of CINV are on the verge of emergence such as 5-HT3 receptor antagonist, NK-1 blocker, corticosteroids, cannabinoids and dopamine antagonists. However, there are several unmet medical needs in the field of HEC regimen of delayed CINV.
Global CINV market has increased at a significant CAGR during the years 2013-2015 and projections are made that the market would rise tremendously in the next four years i.e. 2016-2020. The CINV market is expected to increase due to growth in global cancer incidence, increasing health expenditure and the increasing outbreak of factors working towards causing cancer. Yet, the market faces some challenges such as discontinuation of chemotherapy treatment, several unmet medical needs, no drugs for the HEC regimen in the delayed CINV, etc.
2.1 Chemotherapy: An Overview
2.1.1 Side-Effects of Chemotherapy
2.1.2 Delivery Methods of Chemotherapy
2.1.3 Types of Chemotherapy Drugs
2.1.4 Pros & Cons of Chemotherapy
2.2 CINV: An Overview
2.2.1 Types of CINV
2.2.2 CINV Mechanism
2.2.3 Regimens Causing CINV
2.2.4 Treatment/Prevention of CINV
3. Global Market Analysis
3.1 Global CINV Market: An Analysis
3.1.1 Global CINV Market Opportunity
3.1.2 Global CINV Market by Value
3.2 Global NK-1 Drug Receptor Antagonist Market
3.2.1 Global VARUBI Sales
3.2.2 Global Emend (Injectable) Sales
3.3 Global 5-HT3 Drug Receptor Antagonist Market
3.3.1 Global Aloxi (Injectable) Sales
3.3.2 Global Granisetron (Injectable) & Ondansetron (Injectable) Sales
4. Regional Market Analysis
4.1 North America CINV Market: An Analysis
4.1.1 North America CINV Market by Value
4.1.2 US CINV Market Opportunity
4.1.3 US CINV Market by Drugs Prescription
5. Market Dynamics
5.1 Growth Driver
5.1.1 Rising Global Incidence of Cancer
5.1.2 Widening Causes of Cancer
5.1.3 Rising Global Healthcare Expenditure
5.2.1 No Drug for Delayed CINV- HEC Regimens
5.2.2 Unmet Medical Needs
5.2.3 Discontinuation of Chemotherapy Treatment
5.2.4 Under-Utilized Antagonists
5.3 Market Trends
5.3.1 Breakthrough CINV
5.3.2 Side-Effects of Chemotherapy
5.3.3 Need for Inclusion of NK1 Blocker
5.3.4 Availability of Generic Products
6. Competitive Landscape
6.1 CINV Market Players by Agents Approved and In Development
6.2 Global CINV Product : NK1 Receptor Antagonists
7. Company Profile
7.1 Heron Therapeutics, Inc.
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 Merck & Co., Inc.
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Novartis AG
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 TESARO, Inc.
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
List of Figures
Figure 1: Side-Effects of Chemotherapy
Figure 2: Delivery Methods of Chemotherapy
Figure 3: Types of Chemotherapy Drugs
Figure 4: Pros & Cons of Chemotherapy
Figure 5: Types of CINV
Figure 6: CINV Mechanism
Figure 7: Regimens Causing CINV
Figure 8: Treatment/Prevention of CINV
Figure 9: Global CINV Market Opportunity; 2015
Figure 10: Global CINV Market by Value; 2013-2015 (US$ Billion)
Figure 11: Global CINV Market by Value; 2016-2020 (US$ Billion)
Figure 12: Global VARUBI Sales; 2016-2020 (US$ Million)
Figure 13: Global Emend (Injectable) Sales; 2009-2015 (Thousand)
Figure 14: Global Aloxi (Injectable) Sales; 2009-2015 (Million)
Figure 15: Global Granisetron Sales; 2009-2015 (Thousand)
Figure 16: Global Ondansetron Sales; 2009-2015 (Million)
Figure 17: North America CINV Market by Value; 2013-2015 (US$ Million)
Figure 18: North America CINV Market by Value; 2016-2020 (US$ Million)
Figure 19: US CINV Market Opportunity; 2015
Figure 20: US CINV Market by Drugs Prescription; 2015 (Million)
Figure 21: US 5-HT3 Drug Prescription by Segments; 2015
Figure 22: Global Incidence of Cancer; 2012-2019 (Million)
Figure 23: Causes of Cancer; 2014
Figure 24: Global Healthcare Expenditure; 2009-2014 (US$ Trillion)
Figure 25: Unmet Needs in Prevention of CINV
Figure 26: Discontinuation of Chemotherapy Treatment
Figure 27: Breakthrough CINV by Regimen; 2015 (Percentage, %)
Figure 28: Breakthrough CINV by Occurrence; 2015
Figure 29: Heron Net Loss; 2011-2015 (US$ Billion)
Figure 30: Heron Research & Development Expenditure; 2011-2015 (US$ Million)
Figure 31: Merck & Co., Inc. Sales; 2011-2015 (US$ Billion)
Figure 32: Merck & Co., Inc. Sales by Segments; 2015
Figure 33: Novartis AG Business Segments
Figure 34: Novartis AG Total Sales; 2011-2015 (US$ Billion)
Figure 35: Novartis AG Sales by Segments; 2015
Figure 36: TESARO, Inc. Net Loss; 2011-2015 (US$ Million)
Figure 37: TESARO, Inc. Research & Development Expenditure; 2011-2015 (US$ Million)
List of Tables
Table 1 : Regimens Causing CINV
Table 2: Drugs for CINV
Table 3: Side-Effects of Chemotherapy
Table 4: CINV Market Players by Agents Approved and In Development
Table 5: Comparison of NK1 Receptor Antagonists
The author's core strengths include a seasoned management team, a highly demonstrable track record of seamless process integration and consistent delivery position. The research team uses its extensive knowledge of the various industries to analyze the market trends from both a vendor and an end-user perspective.
The research strategy is focused on high-quality secondary data combined with elaborate use of primary data. The team of research analysts provides a 360-degree overview of available data.
The analysts begin by searching industry reports, surveys, trade publications, company reports and press releases. They also include information gained by extensive interviews with major players and industry participants.
The background information, related to industry statistics, is provided by the author's proprietary databases.
The information is then analyzed and synthesized into a report - with market forecast, industry trends, and competitive strategies. The team of research analysts use both qualitative tools and quantitative techniques to get an insight into the industry.
The author's core expertise lies in researching, compiling and analyzing vast amounts of publicly available information and premier databases, into widely read reports.